The firm shows a Beta (market volatility) of 0.3987, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Advaxis's beta means in this case. As returns on the market increase, Advaxis returns are expected to increase less than the market. However, during the bear market, the loss on holding Advaxis will be expected to be smaller as well. Even though it is essential to pay attention to
Advaxis historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Advaxis exposes twenty-seven different technical indicators, which can help you to evaluate its performance.
Advaxis has an expected return of -0.56%. Please be advised to confirm Advaxis
jensen alpha,
potential upside, as well as the
relationship between the Potential Upside and
accumulation distribution to decide if
Advaxis stock performance from the past will be repeated at some point in the near future.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Ayala Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential Ayala Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Ayala Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ayala Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ayala Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Ayala Pharmaceuticals
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Ayala Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Ayala Pharmaceuticals shares is the value that is considered the true value of the share. If
the intrinsic value of Ayala is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Ayala Pharmaceuticals. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring Ayala Pharmaceuticals on a daily basis if you are holding a position in it. Ayala Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Ayala Pharmaceuticals stock to be traded above the $1 level to remain listed. If Ayala Pharmaceuticals otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Ayala Pharmaceuticals's Liquidity
Ayala Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Ayala Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ayala Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Ayala Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Ayala Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Ayala Pharmaceuticals's total debt and its cash.
Details
The big decline in price over the last few months for Advaxis could raise concerns from retail investors as the firm it trading at a share price of
0.44 on slow start in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in
August. However, diversifying your holdings with Advaxis or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.42. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Advaxis partners.
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Advaxis has an asset utilization ratio of 0.15 percent. This connotes that the company is making $0.001503 for each dollar of assets. An increasing asset utilization means that Advaxis is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 47.55 Million | 72.87 |
| Assets Non Current | 8.88 Million | 13.6 |
| Goodwill | 4.63 Million | 7.1 |
| Tax Assets | 4.19 Million | 6.43 |
Advaxis possible correction in October
The market risk adjusted performance is down to -2.25 as of today. Advaxis exhibits very low volatility with skewness of -1.44 and kurtosis of 11.73. However, we advise investors to further study Advaxis technical indicators to make sure all market info is available and is reliable. Advaxis is a potential penny stock. Although Advaxis may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Advaxis. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Final Take On Advaxis
While other entities in the biotechnology industry are either recovering or due for a correction, Advaxis may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Advaxis valuation and our trade advice on Advaxis is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Advaxis.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Ayala Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com